JP2023133525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023133525A5 JP2023133525A5 JP2023126665A JP2023126665A JP2023133525A5 JP 2023133525 A5 JP2023133525 A5 JP 2023133525A5 JP 2023126665 A JP2023126665 A JP 2023126665A JP 2023126665 A JP2023126665 A JP 2023126665A JP 2023133525 A5 JP2023133525 A5 JP 2023133525A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- cancer
- antibody
- medicament according
- severity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936168P | 2014-02-05 | 2014-02-05 | |
| US61/936,168 | 2014-02-05 | ||
| JP2016550261A JP2017507931A (ja) | 2014-02-05 | 2015-02-05 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2020144077A JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144077A Division JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023133525A JP2023133525A (ja) | 2023-09-22 |
| JP2023133525A5 true JP2023133525A5 (https=) | 2023-12-04 |
| JP7767361B2 JP7767361B2 (ja) | 2025-11-11 |
Family
ID=53778458
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550261A Pending JP2017507931A (ja) | 2014-02-05 | 2015-02-05 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2020144077A Active JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2023126665A Active JP7767361B2 (ja) | 2014-02-05 | 2023-08-03 | がん及び感染症の治療方法並びに治療用組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550261A Pending JP2017507931A (ja) | 2014-02-05 | 2015-02-05 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2020144077A Active JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11213583B2 (https=) |
| EP (2) | EP4736852A2 (https=) |
| JP (3) | JP2017507931A (https=) |
| CN (1) | CN105979961B (https=) |
| CA (1) | CA2937035A1 (https=) |
| WO (1) | WO2015120198A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011133636A1 (en) | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| WO2015120198A1 (en) * | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| WO2015125652A1 (ja) * | 2014-02-21 | 2015-08-27 | Ｉｄａｃセラノスティクス株式会社 | 固形がんの治療剤 |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| ES2818800T3 (es) * | 2014-06-11 | 2021-04-14 | Idac Theranostics Inc | Método para reducir los efectos secundarios de un agente de control del punto de control inmunitario |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| AU2015358334A1 (en) * | 2014-12-05 | 2017-06-08 | Dana-Farber Cancer Institute, Inc. | Bromodomain inhibitor as adjuvant in cancer immunotherapy |
| US20180296663A1 (en) * | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| ES2889904T3 (es) | 2015-08-18 | 2022-01-14 | Rakuten Medical Inc | Conjugados de colorante de ftalocianina y su almacenamiento |
| US11154620B2 (en) | 2015-08-18 | 2021-10-26 | Rakuten Medical, Inc. | Compositions, combinations and related methods for photoimmunotherapy |
| US10526413B2 (en) | 2015-10-02 | 2020-01-07 | Hoffmann-La Roche Inc. | Bispecific antibodies specific for OX40 |
| EP3464360B1 (en) | 2016-05-27 | 2025-11-12 | Agenus Inc. | Anti-tim-3 antibodies and methods of use thereof |
| WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| EP3496707A4 (en) * | 2016-08-09 | 2020-03-25 | Angimmune, LLC | Treatment of cancer using a combination of immunomodulation and check point inhibitors |
| JP7066696B2 (ja) | 2016-10-11 | 2022-05-13 | アジェナス インコーポレイテッド | 抗ｌａｇ－３抗体及びその使用方法 |
| US11407831B2 (en) * | 2017-10-30 | 2022-08-09 | Ube Industries, Ltd. | Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent |
| KR102721494B1 (ko) * | 2018-04-17 | 2024-10-24 | 국립암센터 | 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도 |
| CA3113259A1 (en) * | 2018-09-27 | 2020-04-02 | Genocea Biosciences, Inc. | Treatment methods |
| KR102300846B1 (ko) * | 2019-11-01 | 2021-09-09 | 서울대학교산학협력단 | 면역 활성 개선용 조성물 및 이의 방법 |
| CN114980919B (zh) * | 2019-11-18 | 2026-04-14 | 儿童医学中心公司 | 过度活化驻留树突状细胞的刺激物用于癌症免疫疗法 |
| WO2021155305A1 (en) * | 2020-01-30 | 2021-08-05 | Apeximmune Therapeutics Inc. | Methods and compositions for treating cancer or viral infection with a pla2g2d antagonist |
| CN113045661B (zh) | 2021-04-07 | 2022-06-21 | 中美冠科生物技术（太仓）有限公司 | 新型抗cd4抗体 |
| EP4661908A1 (en) * | 2023-02-06 | 2025-12-17 | GMP Biotechnology Limited | Mtor therapeutics for cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| GB2302353B (en) | 1995-06-21 | 1998-11-11 | British Gas Plc | Method of filling an excavated opening |
| GB0217777D0 (en) | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
| US7438907B2 (en) | 2002-11-15 | 2008-10-21 | Genmab A/S | Human monoclonal antibodies against CD25 |
| CA2585776A1 (en) | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| US20090317407A1 (en) * | 2006-05-02 | 2009-12-24 | Lacelle Michael G | Augmentation of immune response to cancer vaccine |
| US20090311249A1 (en) | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
| WO2007149814A1 (en) | 2006-06-19 | 2007-12-27 | Wyeth | Methods of modulating il-22 and il-17 |
| WO2008005469A2 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
| AU2009288730B2 (en) * | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| PT2374883T (pt) * | 2008-12-26 | 2016-10-20 | Kyowa Hakko Kirin Co Ltd | Anticorpo anti-cd4 |
| EP2375897A4 (en) | 2009-01-14 | 2013-05-15 | Health Research Inc | METHOD AND COMPOSITIONS USING MTOR-INHIBITORS FOR IMPROVING IMMUNE REACTIONS |
| WO2010124498A1 (en) | 2009-04-30 | 2010-11-04 | Beijing Cellonis Biotechnology Co., Ltd | A resistance-screened tumor stem cell, its antigen composition, an anti-tumor dendritic cell loading with said antigens, their preparation methods, uses and kits thereof as well as a dendritic cell vaccine |
| CA3253628A1 (en) * | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| WO2011133636A1 (en) | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS |
| WO2011139738A2 (en) * | 2010-04-28 | 2011-11-10 | Tenx Biopharma, Inc. | Therapies using zanolimumab to enhance the immune response |
| EP2758080B1 (en) * | 2011-09-19 | 2018-03-07 | The Johns Hopkins University | Cancer immunotherapy |
| WO2015120198A1 (en) * | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| CN106413751A (zh) * | 2014-05-21 | 2017-02-15 | 辉瑞大药厂 | 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合 |
| ES2744936T3 (es) | 2014-12-02 | 2020-02-26 | Univ Tokyo | Método para evaluar el efecto terapéutico de un agente antineoplásico que tiene un anticuerpo anti-CD4 como principio activo |
-
2015
- 2015-02-05 WO PCT/US2015/014687 patent/WO2015120198A1/en not_active Ceased
- 2015-02-05 EP EP25223466.1A patent/EP4736852A2/en active Pending
- 2015-02-05 US US15/116,485 patent/US11213583B2/en active Active
- 2015-02-05 JP JP2016550261A patent/JP2017507931A/ja active Pending
- 2015-02-05 CN CN201580007415.4A patent/CN105979961B/zh active Active
- 2015-02-05 CA CA2937035A patent/CA2937035A1/en active Pending
- 2015-02-05 EP EP15747022.0A patent/EP3102233B1/en active Active
-
2020
- 2020-08-28 JP JP2020144077A patent/JP7328187B2/ja active Active
-
2021
- 2021-11-22 US US17/533,065 patent/US20220152198A1/en active Pending
-
2023
- 2023-08-03 JP JP2023126665A patent/JP7767361B2/ja active Active